In early 2022, the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency (MHRA) issued 10 proposals regarding the regulation of clinical trials in the UK. These proposals aim to revise the current Medicines for Human Use (Clinical Trials) Regulations. The revisions focus on the following key areas:
The revised legislation will include a requirement for the involvement of people with relevant lived experience in the design, management, conduct and dissemination of clinical trials, to improve quality and relevance to participants and embed patient engagement in the development pathway for medicine. This is consistent with the current expectations of UK Research Ethics Committees (REC) whereby researchers are expected to involve patients and the public in the design, management, conduct and dissemination of research, however, is not stipulated in the current Medicines for Human Use (Clinical Trials) Regulations 2004, as amended. It is further proposed that clear guidance will be issued in tandem to ensured unified messaging across funders and regulators and consistent review by RECs.
The revised legislation will include a requirement to register a trial in a World Health Organisation (WHO) compliant public register prior to its start. Further, it will also include a requirement to publish a summary of results within 12 months of the end of the trial and that clinical trial findings are further shared with participants in a suitable format. Registration of a study in a WHO compliant registry is consistent with current expectations of UK RECs when a positive opinion for a clinical trial is given. Also notable is that any clinical trial application progressed in accordance with the Combined Review process shall automatically be registered in the ISRCTN registry. Publication of trial results within 12 months of the end of trial is also consistent with the process as has been observed under the Clinical Trials Directive. A new requirement is the publication of results in lay language, which is considered consistent with the revision to the European framework for clinical trials under the newly implemented Clinical Trials Regulation.
Further to the implementation of the Combined Review process on 1st January 2022, the proposed revisions to the legislation will account for this process, cognisant that in the current format separate regulatory and ethical approvals are implied. It is however noteworthy that the revised legislation will continue to permit separate applications as an exception.
The requirement for a EudraCT number will no longer apply under the proposed revisions, consequently a UK-specific trial reference number will be assigned (IRAS number) automatically at the time of preparation of an application. It is proposed that the maximum timeframe for a study to obtain approval would be 30 calendar days from acknowledgment, with a proposal to allow sponsor organisations up to 60 calendar days to respond to any request for further information, with a final decision being given in 10 calendar days from receipt of responses. Within the current Medicines for Human Use (Clinical Trials) Regulations 2004, as amended, the timeline for approval where there is a request for further information is 60 calendar days with a period of 14 calendar days given to respond to queries.
The revised legislation will further permit sponsor organisations the opportunity to withdraw an application from review, thereby negating the potential for study rejections. In the case of requests for further information it is also noteworthy that it is proposed that questions on individual parts of an application can be issued when ready, consequently quality, non-clinical and clinical questions may filter through at different rates during assessment. Of further note is the proposal to implement a sunset provision on clinical trial approvals, whereby if no participants are enrolled to a given study within a specified time period that the trial approval will lapse unless an extension is sought by the trial sponsor.
With regards to amending a study approval it is proposed that the legislation shall be updated to allow for request for information to be issued to reduce chances of such applications being rejected, based on the current provisions within the Medicines for Human Use (Clinical Trials) Regulations 2004, as amended.
It is further proposed to introduce a notification scheme for low-intervention trials, whereby only ethical approval would be required to initiate such a study. The proposal defines a low-intervention trial as, “Trials where the risk is similar to that of standard medical care, e.g. they involve marketed product(s) either used in accordance with the marketing authorisation or supported by (nationally accepted) published evidence and/or guidance and /or established medical practice”, which is broadly consistent with the definition as given by the Organisation for Economic Co-operation and Development (OECD) and that given in the EU Clinical Trials Regulation. It is however noteworthy that in the case of marketed products, these must be licenced in the UK.
It is proposed to streamline requirements for the make-up of ethics committee with updates to the minimum number of members and definitions of lay and expert members in line with international standards, retaining the need for a mix of lay and expert members. Further it proposed that Schedule 2 of the current Medicines for Human Use (Clinical Trials) Regulations 2004, as amended, will be deleted, and replaced by guidance and/or Health Research Authority (HRA) policy to allow for greater agility in decision making.
It is also suggested that legislative requirements may be introduced concerning the inclusion of underserved populations and increase diversity in clinical research.
It is proposed to streamline requirements by introducing a simplified/low burden means of seeking consent from participants for low-intervention clinical trials where the investigational medicinal product is pre-determined based on location and are used in accordance with the terms of the marketing authorisation i.e., “cluster trials”. Simplifying the approach for consent in these large-scale randomised studies is perceived as supporting their use and facilitating the gathering of real-world evidence and consequently support wider uptake into such lower risk trials.
It is proposed to remove reporting requirements that add burden to investigators but do not contribute to participant safety whilst maintaining the highest standards of participant safety. Included within the suggestions are removal of the requirement for individual SUSARs to be reported to all investigators, remove the requirement to report SUSARs and annual safety reports to RECs, introduce flexibility in the reporting of SUSARs an allowing for reporting in an aggregate manner, introduce a legal requirement for Sponsors to have a pharmacovigilance system aimed at periodically reviewing accumulated safety data for signal detection, remove the requirement to have listings of serious adverse events and serious adverse reaction in annual safety reports, and to extend the notification period for urgent safety measures from 3 days to 7 days.
Compliance with the broad principles of GCP to protect the right and well-being of trial participants and the reliability of trial results is to be maintained, however UK principles will be clarified within the legislation. The proposal centres on ensuring that UK GCP principles are flexible and applicable to a broad range of clinical trials and will include identification of critical to quality factors, risk proportionality, and will support more efficient approaches to trial design and conduct. Specific changes referenced in the MHRA publication include risk proportionality and regulators taking a proportionate approach throughout the clinical trial life cycle, future proofing GCP principles for electronic systems by introducing clarity over the design and control of such systems that impact on safety and results, trial master files, and clarifications regarding participants not bearing any financial cost to take part in a clinical trial.
It is proposed to expand the current Enforcement and Related provisions given in Part 8 of the current Medicines for Human Use (Clinical Trials) Regulations 2004, as amended, by introducing the ability for the regulators to refuse to approve a new study based on ongoing serious non-compliance with the legislation where there could be significant harm to participants. It is further stipulated that in respect of suspension or termination of a clinical trial by the regulators that proportionate actions shall be taken and therefore a whole trial may not need to stop as is the current case. It is also noteworthy that the proposals indicate further legislation being introduced to address the right to appeal of any decisions taken.
It is noteworthy that the MHRA are stipulating that there is no intent to align with the EU Clinical Trials Regulation in respect of investigational medicinal product labelling requirements nor the adoption of the definition of an auxiliary medicinal product. It is proposed that the legislation will be updated to include the term “non-investigational medicinal product” (NIMP) to extend the concept to non-medicinal products that may currently be unregulated. It is further proposed that risk-proportionate requirements to labelling of investigational products will be applied.
It is also further proposed to make an exemption from the need to hold a Manufacturers Authorisation for IMPs (MIA(IMP)) for the preparation of radiopharmaceuticals used as diagnostic IMPs where the process is carried out in hospitals, health centres or clinics, thereby expanding the current exemptions permitted under the current Medicines for Human Use (Clinical Trials) Regulations 2004, as amended. It would however remain a requirement that any radiopharmaceutical used in a clinical trial would still need to be manufactured to an appropriate level of GMP and consequently facilities will still need to hold a manufacturing specials license.
The revisions to the UK legislation are accompanied by a number of proposed changes to definitions to promote international harmonisation. Of note in the proposals published are clarifications on the role of sponsors and the ability to co-sponsor trials, that informed consent may be sought by any member of the investigator’s team when qualified by education, training or experience, expanding the professional groups who can be an Investigator, permit data collection after MHRA early access approval without need for Clinical Trial Authorisation, and to permit non-interventional long term follow up information to be collected after intervention end without the need for regulatory approval.
These revisions aim to make the UK an attractive destination for the development of new innovations in healthcare. By reframing clinical trial legislation, sponsors may experience a more streamlined, transparent, and flexible regulatory regime which also protects patients and trial participants.
Click here to read more about the objectives driving the proposed revisions >
Chris Ingram, BSc (Hons) is Head of Regulatory Consultancy (Europe) for Precision for Medicine. Chris received his BSc(Hons) in immunology and pharmacology from the University of Strathclyde and has since spent over 21 years working in regulatory affairs with a focus on clinical development. Chris’ regulatory expertise covers clinical development across all phases, regulatory strategy, marketing authorisations, scientific advice, orphan drug designation and paediatric investigation plans across a wide variety of therapeutic areas, including but not limited to, oncology, CNS, metabolic, endocrinology, analgesia and cardiovascular.
Precision for Medicine is part of the Precision Medicine Group, an integrated team of experts that extends Precision for Medicine’s therapeutic development capabilities beyond approval and into launch strategies, marketing communication, and payer insights. As one company, the Precision Medicine Group helps pharmaceutical and life-sciences clients conquer product development and commercialization challenges in a rapidly evolving environment.
